Overview

Evaluation of Dosing Interval of Higher Doses of Ranibizumab

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Evaluation of Dosing Interval of Higher Doses of Ranibizumab for patients with wet age-related macular degeneration (AMD).
Phase:
Phase 4
Details
Lead Sponsor:
Brandon G. Busbee, MD
Collaborator:
Genentech, Inc.
Treatments:
Ranibizumab